These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18572388)

  • 1. Varenicline efficacy and tolerability in a subject with schizophrenia.
    Fatemi SH
    Schizophr Res; 2008 Aug; 103(1-3):328-9. PubMed ID: 18572388
    [No Abstract]   [Full Text] [Related]  

  • 2. Varenicline modulates spatial working memory deficits in smokers with schizophrenia.
    Wing VC; Wass CE; Bacher I; Rabin RA; George TP
    Schizophr Res; 2013 Sep; 149(1-3):190-1. PubMed ID: 23849883
    [No Abstract]   [Full Text] [Related]  

  • 3. Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies.
    Cerimele JM; Durango A
    J Clin Psychiatry; 2012 Aug; 73(8):e1039-47. PubMed ID: 22967780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder.
    Williams JM; Anthenelli RM; Morris CD; Treadow J; Thompson JR; Yunis C; George TP
    J Clin Psychiatry; 2012 May; 73(5):654-60. PubMed ID: 22697191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study.
    Fatemi SH; Yousefi MK; Kneeland RE; Liesch SB; Folsom TD; Thuras PD
    Schizophr Res; 2013 May; 146(1-3):376-8. PubMed ID: 23507358
    [No Abstract]   [Full Text] [Related]  

  • 6. Varenicline induced polydipsia and hyponatremia in a patient with schizophrenia.
    Ismail Z; Syms J; Blumberger D; George TP
    Schizophr Res; 2010 Jun; 119(1-3):268. PubMed ID: 20178890
    [No Abstract]   [Full Text] [Related]  

  • 7. Exacerbation of recurrent depression as a result of treatment with varenicline.
    Popkin MK
    Am J Psychiatry; 2008 Jun; 165(6):774. PubMed ID: 18519539
    [No Abstract]   [Full Text] [Related]  

  • 8. Varenicline for smoking cessation: definite promise, but no panacea.
    Klesges RC; Johnson KC; Somes G
    JAMA; 2006 Jul; 296(1):94-5. PubMed ID: 16820552
    [No Abstract]   [Full Text] [Related]  

  • 9. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study.
    Weiner E; Buchholz A; Coffay A; Liu F; McMahon RP; Buchanan RW; Kelly DL
    Schizophr Res; 2011 Jun; 129(1):94-5. PubMed ID: 21376537
    [No Abstract]   [Full Text] [Related]  

  • 10. Varenicline prevents affective and cognitive exacerbation during smoking abstinence in male patients with schizophrenia.
    Liu ME; Tsai SJ; Jeang SY; Peng SL; Wu SL; Chen MC; Tsai YL; Yang ST
    Psychiatry Res; 2011 Nov; 190(1):79-84. PubMed ID: 21636135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varenicline in smoking cessation.
    Tonstad S; Rollema H
    Expert Rev Respir Med; 2010 Jun; 4(3):291-9. PubMed ID: 20524911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Varenicline (Chantix) for tobacco dependence.
    Med Lett Drugs Ther; 2006 Aug 14-28; 48(1241-1242):66-8. PubMed ID: 16977281
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effectiveness and safety of varenicline for smoking cessation].
    Christalla P; Dewenter M; El-Armouche A
    Dtsch Med Wochenschr; 2012 May; 137(18):940-4. PubMed ID: 22492478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
    Lam S; Patel PN
    Cardiol Rev; 2007; 15(3):154-61. PubMed ID: 17438382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study.
    Bolliger CT; Issa JS; Posadas-Valay R; Safwat T; Abreu P; Correia EA; Park PW; Chopra P
    Clin Ther; 2011 Apr; 33(4):465-77. PubMed ID: 21635992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.
    Hong LE; Thaker GK; McMahon RP; Summerfelt A; Rachbeisel J; Fuller RL; Wonodi I; Buchanan RW; Myers C; Heishman SJ; Yang J; Nye A
    Arch Gen Psychiatry; 2011 Dec; 68(12):1195-206. PubMed ID: 21810630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
    Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
    Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful smoking cessation and improvement of negative symptoms with varenicline in a stable schizophrenia patient.
    Anghelescu I
    J Neuropsychiatry Clin Neurosci; 2009; 21(1):102-3. PubMed ID: 19359464
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA speeds smoking cessation drug review.
    Kuehn BM
    JAMA; 2006 Feb; 295(6):614. PubMed ID: 16467225
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.